Can the Use of ?-Adrenergic Blockers for Treatment of HFpEF Worsen Diastolic Dysfunction? - A Review Based on Concept of MyBP-C
AbstractHeart failure can be classified based on ejection fraction as reduced Heart Failure Reduced Ejection Fraction (HFrEF), moderate Heart Failure Moderate Ejection Fraction (HFmEF) and preserved Heart Failure Preserved Ejection Fraction (HFpEF). Indeed, use of beta-blockers in Heart Failure (HF) reduces mortality and morbidity. However, the controversial effect of the use of beta-blockers in HFpEF is of great concern. HFpEF is associated with a high mortality and hospitalization rate probably due to lack of evidence-based treatment. Hence a proper understanding behind the pathophysiologic mechanism of HFpEF is important. Recently Myosin Binding Protein C
. Lam, C.S.P., et al., Epidemiology and clinical course of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2011. 13(1): p. 18-28.
. Owan, T., et al., Trends in prevalence and outcome of heart failure with preserved ejection fraction. The New England Journal of Medicine, 2009. 355(3): p. 251-259.
. Mathers, C., et al., Causes of international increases in older age life expectancy. The Lancet, 2015. 385(9967): p. 540-548.
. Brouwers, F.P., et al., Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. European Heart Journal, 2013. 34(19): p. 1424-1431.
. Fonarow, G.C., et al., Characteristics, Treatments, and Outcomes of Patients With Preserved Systolic Function Hospitalized for Heart Failure. Journal of the American College of Cardiology, 2007. 50(8): p. 768-777.
. Yancy, C.W., et al., Clinical Presentation, Management, and In-Hospital Outcomes of Patients Admitted With Acute Decompensated Heart Failure With Preserved Systolic Function. Journal of the American College of Cardiology, 2006. 47(1): p. 76-84.
. Paulus, W.J., et al., How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. European Heart Journal, 2007. 28(21): p. 2686-2687.
. Nagueh, S.F., et al., Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography. Journal of The American Society of Echocardiography, 2009. 22(2): p. 107-133.
. Redfield, M.M., et al., Burden of Systolic and Diastolic Ventricular Dysfunction in the Community: Appreciating the Scope of the Heart Failure Epidemic. JAMA, 2003. 289(2): p. 194-202.
. Mcmurray, J.J.V., et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. European Heart Journal, 2012. 33(14): p. 1787-1847.
. Yancy, C.W., et al., 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 2013. 62(16).
. Zile, M.R., et al., Prevalence and Significance of Alterations in Cardiac Structure and Function in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation, 2011. 124(23): p. 2491-2501.
. Cheng, J.M., et al., Biomarkers of heart failure with normal ejection fraction: a systematic review. European Journal of Heart Failure, 2013. 15(12): p. 1350-1362.
. Morrow, D.A. and J.A. De Lemos, Benchmarks for the Assessment of Novel Cardiovascular Biomarkers. Circulation, 2007. 115(8): p. 949-952.
. Chatterjee, S., et al., Benefits of ? blockers in patients with heart failure and reduced ejection fraction: network meta-analysis. BMJ, 2013. 346.
. Liu, F., et al., Effects of Beta-Blockers on Heart Failure with Preserved Ejection Fraction: A Meta-Analysis. PLOS ONE, 2014. 9(3).
. Bavishi, C., et al., Beta-blockers in heart failure with preserved ejection fraction: a meta-analysis. Heart Failure Reviews, 2014. 20(2): p. 193-201.
. Starr, E.R., et al., Phosphorylation of cardiac myosin binding protein-C regulates heart contraction and dilatation in vivo during ?-adrenergic receptor activation. The Journal of Physiology, 2016. 594(14): p. 4015-4016.
. Previs, M.J., et al., Phosphorylation and calcium antagonistically tune myosin-binding protein C's structure and function. Proceedings of the National Academy of Sciences of the United States of America, 2016. 113(12): p. 3239-3244.
. Fu, Q., X. Chen, and Y.K. Xiang, Compartmentalization of ?-adrenergic signals in cardiomyocytes. Trends in Cardiovascular Medicine, 2013. 23(7): p. 250-256.
. Gresham, K.S. and J.E. Stelzer, The contributions of cardiac myosin binding protein C and troponin I phosphorylation to ??adrenergic enhancement of in vivo cardiac function. The Journal of Physiology, 2016. 594(3): p. 669-686.
. Moss, R.L., D.P. Fitzsimons, and J.C. Ralphe, Cardiac MyBP-C Regulates the Rate and Force of Contraction in Mammalian Myocardium. Circulation Research, 2015. 116(1): p. 183-192.
. Tong, C.W., et al., Phosphoregulation of Cardiac Inotropy via Myosin Binding Protein-C During Increased Pacing Frequency or ?1-Adrenergic Stimulation. Circulation-heart Failure, 2015. 8(3): p. 595-604.
. Biesiadecki, B.J., et al., Tri-modal regulation of cardiac muscle relaxation; intracellular calcium decline, thin filament deactivation, and cross-bridge cycling kinetics. Biophysical Reviews, 2014. 6: p. 273-289.
. Tong, C.W., et al., Acceleration of Crossbridge Kinetics by Protein Kinase A Phosphorylation of Cardiac Myosin Binding Protein C Modulates Cardiac Function. Circulation Research, 2008. 103(9): p. 974-982.
. Frey, N., M. Luedde, and H.A. Katus, Mechanisms of disease: hypertrophic cardiomyopathy. Nature Reviews Cardiology, 2012. 9(2): p. 91-100.
. Van Dijk, S.J., et al., Contractile Dysfunction Irrespective of the Mutant Protein in Human Hypertrophic Cardiomyopathy With Normal Systolic Function. Circulation-heart Failure, 2012. 5(1): p. 36-46.
. Rosas, P.C., et al., Phosphorylation of Cardiac Myosin-Binding Protein-C Is a Critical Mediator of Diastolic Function. Circulation-heart Failure, 2015. 8(3): p. 582-594.
. Figueroa, M.S. and J.I. Peters, Congestive Heart Failure: Diagnosis, Pathophysiology, Therapy, and Implications for Respiratory Care. Respiratory Care, 2006. 51(4): p. 403-412.
. Borlaug, B.A. and W.J. Paulus, Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. European Heart Journal, 2011. 32(6): p. 670-679.
. Borlaug, B.A., et al., Impaired Chronotropic and Vasodilator Reserves Limit Exercise Capacity in Patients With Heart Failure and a Preserved Ejection Fraction. Circulation, 2006. 114(20): p. 2138-2147.
. Kawaguchi, M., et al., Combined Ventricular Systolic and Arterial Stiffening in Patients With Heart Failure and Preserved Ejection Fraction Implications for Systolic and Diastolic Reserve Limitations. Circulation, 2003. 107(5): p. 714-720.
. Lam, C.S.P., et al., Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction. Journal of the American College of Cardiology, 2009. 53(13): p. 1119-1126.
. Maurer, M.S., et al., Ventricular Structure and Function in Hypertensive Participants With Heart Failure and a Normal Ejection Fraction : The Cardiovascular Health Study. Journal of the American College of Cardiology, 2007. 49(9): p. 972-981.
. Maurer, M.S. and S.L. Hummel, Heart Failure With a Preserved Ejection Fraction: What Is in a Name? Journal of the American College of Cardiology, 2011. 58(3): p. 275-277.
. Prasad, A., et al., Characterization of Static and Dynamic Left Ventricular Diastolic Function in Patients With Heart Failure With a Preserved Ejection Fraction. Circulation-heart Failure, 2010. 3(5): p. 617-626.
Authors who submit papers with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
- By submitting the processing fee, it is understood that the author has agreed to our terms and conditions which may change from time to time without any notice.
- It should be clear for authors that the Editor In Chief is responsible for the final decision about the submitted papers; have the right to accept\reject any paper. The Editor In Chief will choose any option from the following to review the submitted papers:A. send the paper to two reviewers, if the results were negative by one reviewer and positive by the other one; then the editor may send the paper for third reviewer or he take immediately the final decision by accepting\rejecting the paper. The Editor In Chief will ask the selected reviewers to present the results within 7 working days, if they were unable to complete the review within the agreed period then the editor have the right to resend the papers for new reviewers using the same procedure. If the Editor In Chief was not able to find suitable reviewers for certain papers then he have the right to accept\reject the paper.B. sends the paper to a selected editorial board member(s). C. the Editor In Chief himself evaluates the paper.
- Author will take the responsibility what so ever if any copyright infringement or any other violation of any law is done by publishing the research work by the author
- Before publishing, author must check whether this journal is accepted by his employer, or any authority he intends to submit his research work. we will not be responsible in this matter.
- If at any time, due to any legal reason, if the journal stops accepting manuscripts or could not publish already accepted manuscripts, we will have the right to cancel all or any one of the manuscripts without any compensation or returning back any kind of processing cost.
- The cost covered in the publication fees is only for online publication of a single manuscript.